S. Slavin, A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker et al., Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant hematologic diseases, Blood, vol.91, pp.756-63, 1998.

P. A. Mcsweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina et al., Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, Blood, vol.97, pp.3390-400, 2001.

S. Giralt, E. Estey, M. Albitar, K. Van-besien, G. Rondon et al., Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy, Blood, vol.89, pp.4531-4537, 1997.

M. Michallet, Q. H. Le, M. Mohty, T. Prebet, F. Nicolini et al., Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire, Exp Hematol, vol.36, pp.535-579, 2008.

D. Blaise, R. Tabrizi, J. M. Boher, L. Corroller-soriano, A. G. Bay et al., Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigenmatched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation, Cancer, vol.119, pp.602-613, 2013.

B. Lioure, M. C. Bene, A. Pigneux, A. Huynh, C. Chevallier et al., Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age adapted strategy: longterm results of a prospective GOELAMS study, Blood, vol.119, pp.2943-2951, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00849702

L. Bourgeois, A. Lestang, E. Guillaume, T. Delaunay, J. Ayari et al., Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT), Eur J Haematol, vol.90, pp.177-86, 2013.

C. Oudin, P. Chevallier, S. Furst, T. Guillaume, E. Cheikh et al., Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies, Haematologica, vol.99, pp.1762-1768, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01325488

M. T. Rubio, M. Labopin, D. Blaise, G. Socié, R. R. Contreras et al., The impact of graft-versus-host disease prophylaxis in reducedintensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Haematologica, vol.100, pp.683-689, 2015.

M. Mohty, F. Malard, D. Blaise, N. Milpied, S. Frust et al., Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial, Cancer, vol.121, pp.562-571, 2015.

M. A. Kharfan-dabaja, M. Labopin, A. Bazarbachi, R. M. Hamladji, D. Blaise et al., Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT, Bone Marrow Transplant, vol.49, pp.1170-1175, 2014.

M. A. Kharfan-dabaja, M. Labopin, A. Bazarbachi, G. Socié, N. Kroeger et al., Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leuk Res, vol.39, pp.933-940, 2015.

P. S. Becker, H. M. Kantarjian, F. R. Appelbaum, B. Storer, S. Pierce et al., Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colonystimulating factor as salvage therapies for acute myeloid leukemia, Haematologica, vol.98, pp.114-118, 2013.

A. Molteni, M. Riva, E. Ravano, L. Marbello, V. Mancini et al., Clofarabine_ based chemotharapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience, Int J Hematol, vol.105, pp.769-776, 2017.

X. Thomas, S. De-botton, S. Chevret, D. Caillot, E. Raffoux et al., Randomized Phase www.oncotarget.com II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission, J Clin Oncol, vol.35, pp.1223-1230, 2017.

S. Jeha, V. Gandhi, K. W. Chan, L. Mcdonald, I. Ramirez et al., Clofarabine, a novel nucleoside analog is active in pediatric patients with advanced leukemia, Blood, vol.103, pp.784-789, 2004.

S. Jeha, P. S. Gaynon, B. I. Razzouk, J. Franklin, R. Kadota et al., Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia, J Clin Oncol, vol.24, pp.1917-1923, 2006.

P. Chevallier, M. Labopin, G. Socié, R. Tabrizi, S. Frust et al., Result from clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial, Haematologica, vol.99, pp.1486-91, 2014.

P. Kebriaei, R. Bassett, G. Lyons, B. Valdez, C. Ledesma et al., Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results, Biol Blood Marrow Transplant, vol.23, pp.285-292, 2017.

P. Chevallier, M. Labopin, P. De-latour, R. Lioure, B. Bulabois et al., Clofarabine versus Fludarabine-based reduced-intensity conditioning regimen prior allogeneic transplantation in adult with AML/MDS, Cancer Med, vol.5, pp.3068-3076, 2016.

H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner et al., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, European LeukemiaNet. Blood, vol.115, pp.453-74, 2010.

S. G. Holtan, T. E. Defor, A. Lazaryan, N. Bejanyan, M. Arora et al., Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, vol.125, pp.1333-1341, 2015.

A. Ruggeri, M. Labopin, F. Ciceri, M. Mohty, and A. Nagler, Definition of GvHD-free, relapse-free survival for registrybased studies: an ALWP-EBMT analysis on patients with AML in remission, Bone Marrow Transplant, vol.51, pp.610-611, 2016.

M. Aoudjhane, M. Labopin, N. C. Gorin, A. Shimoni, T. Ruutu et al., Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.19, pp.2304-2312, 2005.

M. Balsat, A. Renneville, X. Thomas, S. De-botton, D. Caillot et al., Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group, J Clin Oncol, vol.35, pp.185-193, 2017.

A. Candoni, F. De-marchi, M. E. Zannier, D. Lazzarotto, C. Filì et al., High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission, Leuk Res, vol.63, pp.22-27, 2017.

R. B. Walter, B. Gyurkocza, B. E. Storer, C. D. Godwin, J. M. Pagel et al., Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation, Leukemia, vol.29, pp.137-181, 2015.

F. Lacombe, L. Campos, K. Allou, C. Arnoulet, A. Delabarthe et al., Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia, Hematol Oncol, vol.36, pp.422-428, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01698460

D. Araki, B. L. Wood, M. Othus, J. P. Radich, A. B. Halpern et al., Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?, J Clin Oncol, vol.34, pp.329-365, 2016.

G. J. Schuurhuis, M. Heuser, S. Freeman, M. C. Béné, F. Buccisano et al., Minimal/ measurable residual disease in AML: a consensus document from the, European LeukemiaNet MRD Working Party. Blood, vol.131, pp.1275-1291, 2018.

M. Mohty, J. O. Bay, C. Faucher, B. Choufi, O. Bilger-k-tournilhac et al., Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen, Blood, vol.102, pp.470-476, 2003.

R. Devillier, R. Crocchiolo, L. Castagna, S. Furst, E. Cheikh et al., The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients www.oncotarget.com with myeloid malignancies undergoing allo-SCT, Bone Marrow Transplant, vol.47, pp.639-645, 2012.

R. Crocchiolo, B. Esterni, L. Castagna, S. Furst, J. El-cheikh et al., Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases, Cancer, vol.119, pp.986-92, 2013.

R. S. Mehta, D. Stasi, A. Andersson, B. S. Nieto, Y. Jones et al., The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation, Clin Lymphoma Myeloma Leuk, vol.14, pp.1-5, 2014.

J. Tischer, H. J. Stemmler, N. Engel, M. Hubmann, S. Fritsch et al., Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia, Ann Hematol, vol.92, pp.1379-88, 2013.

K. Rakszawski, K. Miki, D. Claxton, H. Wagner, H. Shike et al., Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and totalbody irradiation with post-transplant cyclophosphamide in non-remission AML, Int J Hematol, vol.108, pp.348-350, 2018.

P. Chevallier, P. Peterlin, A. Garnier, L. Bourgeois, A. Mahé et al., Clofarabine-Based Reduced Intensity Conditioning Regimen with Post-Transplant Cyclophosphamide and Peripheral Stem Cell Graft in Adults with Myeloid Malignancies: Results of the Clo-Baltimore Regimen, Blood, vol.130, 1964.

G. Battipaglia, A. Ruggeri, R. Massoud, E. Cheikh, J. Jestin et al., Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fmslike tyrosine kinase 3-mutated acute myeloid leukemia, Cancer, vol.123, pp.2867-2874, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01777827

T. Guillaume, I. Yakoub-agha, R. Tabrizi, C. Borel, P. Chevallier et al., Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome, Blood, vol.128, 1162.

T. A. Gooley, W. Leisenring, J. Crowley, and B. E. Storer, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, vol.18, pp.695-706, 1999.

H. Glucksberg, R. Storb, A. Fefer, C. D. Buckner, P. E. Neiman et al., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors, Transplantation, vol.18, pp.295-304, 1974.

H. Shulman, K. M. Sullivan, P. L. Weiden, G. B. Mcdonald, G. E. Striker et al., Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients, Am J Med, vol.69, pp.204-221, 1980.